{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:25:26Z","timestamp":1790018726859,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["2023s07020018"],"award-info":[{"award-number":["2023s07020018"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018530","name":"Major Science and Technology Projects in Anhui Province","doi-asserted-by":"publisher","award":["202303a07020007"],"award-info":[{"award-number":["202303a07020007"]}],"id":[{"id":"10.13039\/501100018530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171479"],"award-info":[{"award-number":["32171479"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373715"],"award-info":[{"award-number":["82373715"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007121","name":"Hefei Institutes of Physical Science, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["BJPY2022A02"],"award-info":[{"award-number":["BJPY2022A02"]}],"id":[{"id":"10.13039\/501100007121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.intimp.2025.114839","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:37:21Z","timestamp":1747845441000},"page":"114839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease"],"prefix":"10.1016","volume":"159","author":[{"given":"Jie","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezhong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.intimp.2025.114839_bb0005","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0904958106","article-title":"NOD2 contributes to cutaneous defense against Staphylococcus aureus through alpha-toxin-dependent innate immune activation","volume":"106","author":"Hruz","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6877","key":"10.1016\/j.intimp.2025.114839_bb0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/416194a","article-title":"RICK\/Rip2\/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems","volume":"416","author":"Kobayashi","year":"2002","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2025.114839_bb0015","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ni1131","article-title":"Nod1 responds to peptidoglycan delivered by the helicobacter pylori cag pathogenicity island","volume":"5","author":"Viala","year":"2004","journal-title":"Nat. Immunol."},{"issue":"5625","key":"10.1016\/j.intimp.2025.114839_bb0020","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1126\/science.1084677","article-title":"Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan","volume":"300","author":"Girardin","year":"2003","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.intimp.2025.114839_bb0025","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1074\/jbc.C200651200","article-title":"Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection","volume":"278","author":"Girardin","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.114839_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/imr.12902","article-title":"NOD1 and NOD2 in inflammatory and infectious diseases","volume":"297","author":"Trindade","year":"2020","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2025.114839_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1747","article-title":"Signalling pathways and molecular interactions of NOD1 and NOD2","volume":"6","author":"Strober","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114839_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/imr.12193","article-title":"Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn\u2019s disease","volume":"260","author":"Strober","year":"2014","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2025.114839_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006177","article-title":"Nod2: the intestinal gate keeper","volume":"13","author":"Al Nabhani","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2025.114839_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.abb.2018.12.022","article-title":"NOD1 and NOD2 in inflammation, immunity and disease","volume":"670","author":"Mukherjee","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"6","key":"10.1016\/j.intimp.2025.114839_bb0055","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.molcel.2012.04.014","article-title":"The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity","volume":"46","author":"Damgaard","year":"2012","journal-title":"Mol. Cell"},{"issue":"9853","key":"10.1016\/j.intimp.2025.114839_bb0060","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"7422","key":"10.1016\/j.intimp.2025.114839_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2025.114839_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3565","article-title":"NOD proteins: regulators of inflammation in health and disease","volume":"14","author":"Philpott","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.114839_bb0075","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.intimp.2025.114839_bb0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","article-title":"Novel targeted therapies for inflammatory bowel disease","volume":"38","author":"Coskun","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.114839_bb0085","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2025.114839_bb0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcdb.2020.07.001","article-title":"RIPK2 NODs to XIAP and IBD","volume":"109","author":"Topal","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2025.114839_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650403","article-title":"RIPK2 as a new therapeutic target in inflammatory bowel diseases","volume":"12","author":"Honjo","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2025.114839_bb0100","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/ibd.20907","article-title":"Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohn\u2019s disease","volume":"15","author":"Negroni","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"issue":"12","key":"10.1016\/j.intimp.2025.114839_bb0105","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.dld.2010.04.003","article-title":"Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis","volume":"42","author":"Stronati","year":"2010","journal-title":"Dig. Liver Dis."},{"issue":"10","key":"10.1016\/j.intimp.2025.114839_bb0110","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/intimm\/dxz045","article-title":"RICK\/RIP2 is a NOD2-independent nodal point of gut inflammation","volume":"31","author":"Watanabe","year":"2019","journal-title":"Int. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114839_bb0115","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.chembiol.2015.07.017","article-title":"Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors","volume":"22","author":"Canning","year":"2015","journal-title":"Chem. Biol."},{"issue":"23","key":"10.1016\/j.intimp.2025.114839_bb0120","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1101\/gad.1964410","article-title":"Inhibition of RIP2\u2019s tyrosine kinase activity limits NOD2-driven cytokine responses","volume":"24","author":"Tigno-Aranjuez","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.intimp.2025.114839_bb0125","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/ncomms7442","article-title":"A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production","volume":"6","author":"Nachbur","year":"2015","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2025.114839_bb0130","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1021\/acs.jmedchem.6b00211","article-title":"The identification and pharmacological characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase","volume":"59","author":"Haile","year":"2016","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.intimp.2025.114839_bb0135","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1021\/acs.jmedchem.9b00575","article-title":"Discovery of a first-in-class receptor interacting protein 2 (RIP2) kinase specific clinical candidate, 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases","volume":"62","author":"Haile","year":"2019","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.intimp.2025.114839_bb0140","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1021\/acs.jmedchem.5b01611","article-title":"Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia","volume":"58","author":"Li","year":"2015","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2025.114839_bb0145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.emboj.7601962","article-title":"A critical role of RICK\/RIP2 polyubiquitination in nod-induced NF-kappaB activation","volume":"27","author":"Hasegawa","year":"2008","journal-title":"EMBO J."},{"issue":"24","key":"10.1016\/j.intimp.2025.114839_bb0150","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.cub.2004.12.032","article-title":"The Crohn\u2019s disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO","volume":"14","author":"Abbott","year":"2004","journal-title":"Curr. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114839_bb0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20061704","article-title":"Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide","volume":"404","author":"Windheim","year":"2007","journal-title":"Biochem. J."},{"issue":"50","key":"10.1016\/j.intimp.2025.114839_bb0160","doi-asserted-by":"crossref","first-page":"36223","DOI":"10.1074\/jbc.M703079200","article-title":"NOD2 pathway activation by MDP or mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2025.114839_bb0165","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: Midostaurin for the treatment of advanced systemic Mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.intimp.2025.114839_bb0170","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/fon.14.105","article-title":"Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia","volume":"10","author":"Levis","year":"2014","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114839_bb0175","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cell.2009.05.021","article-title":"Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2025.114839_bb0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5217\/ir.2019.09154","article-title":"Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models","volume":"18","author":"Mizoguchi","year":"2020","journal-title":"Intest Res"},{"issue":"1","key":"10.1016\/j.intimp.2025.114839_bb0185","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.gastro.2014.03.049","article-title":"A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease","volume":"147","author":"Vossenk\u00e4mper","year":"2014","journal-title":"Gastroenterology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692500829X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692500829X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T07:15:13Z","timestamp":1750317313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692500829X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"alternative-id":["S156757692500829X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114839","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114839"}}